Reata Pharmaceuticals Q3 EPS $(1.32) Misses $(1.24) Estimate, Sales $8.24M Beat $7.44M Estimate

Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.24) by 6.45 percent. This is a 23.36 percent decrease over losses of $(1.07) per share

Benzinga · 11/12/2019 11:46

Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.24) by 6.45 percent. This is a 23.36 percent decrease over losses of $(1.07) per share from the same period last year. The company reported quarterly sales of $8.24 million which beat the analyst consensus estimate of $7.44 million by 10.75 percent. This is a 59.23 percent increase over sales of $5.175 million the same period last year.